Table I.
Age-adjusted incidence rates and incidence rate ratios of marginal zone lymphoma according to site and gender, SEER-18, 2001–2009*
| ICD-O-3 | Total | Median age (years) |
Male | Female | Male-to-female | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| topography codes | n | IR | n | IR | n | IR | IRR | (95% CI) | ||
| All sites† | C00.0–80.9 | 13,096 | 18.3 | 67 | 5,996 | 19.0 | 7,100 | 17.9 | 1.06 | (1.02–1.10)‡ |
| All nodal MZL | C77.0–77.9 | 4,081 | 5.7 | 69 | 1,933 | 6.2 | 2,148 | 5.4 | 1.15 | (1.08–1.22)‡ |
| All extranodal MZL | C00.0–41.9, 42.2, 44.0–76.8 | 8,821 | 12.3 | 66 | 3,962 | 12.5 | 4,859 | 12.3 | 1.01 | (0.97–1.06) |
| Oral cavity/oropharynx | ||||||||||
| HPV-related sites | C01.9, 02.4, 09.0–09.9,10.0–10.9, 14.2 | 106 | 0.1 | 69 | 50 | 0.2 | 56 | 0.1 | 1.12 | (0.74–1.67) |
| HPV-unrelated sites | C02.0–02.3, 02.8–06.9 | 89 | 0.1 | 67 | 30 | 0.1 | 59 | 0.1 | 0.68 | (0.42–1.07) |
| Salivary glands | C07.9–08.9 | 638 | 0.9 | 62 | 172 | 0.5 | 466 | 1.2 | 0.43 | (0.36–0.52)‡ |
| Nasopharynx | C11.0–11.9 | 63 | 0.1 | 59 | 34 | 0.1 | 29 | 0.1 | 1.32 | (0.77–2.25) |
| Stomach | C16.0–16.9 | 2,702 | 3.8 | 68 | 1,347 | 4.3 | 1,355 | 3.4 | 1.27 | (1.18–1.37)‡ |
| Small intestine | C17.0–17.9 | 258 | 0.4 | 66 | 134 | 0.4 | 124 | 0.3 | 1.33 | (1.03–1.72)‡ |
| Colon/rectum | C18.0–20.9 | 399 | 0.6 | 68 | 182 | 0.6 | 217 | 0.5 | 1.06 | (0.87–1.30) |
| Lung | C34.0–34.9 | 680 | 1.0 | 68 | 303 | 1.0 | 377 | 1.0 | 1.00 | (0.86–1.17) |
| Spleen | C42.2 | 1,125 | 1.6 | 68 | 531 | 1.7 | 594 | 1.5 | 1.12 | (1.00–1.27) |
| Skin | C44.0–44.9 | 692 | 0.9 | 58 | 402 | 1.2 | 290 | 0.7 | 1.60 | (1.37–1.86)‡ |
| Soft tissue, including heart | C38.0, 47.0–47.9, 49.0–49.9 | 170 | 0.2 | 67 | 63 | 0.2 | 107 | 0.3 | 0.74 | (0.53–1.02) |
| Breast | C50.0–50.9 | 263 | 0.4 | 67 | <16 | ~ | 252 | 0.6 | ~ | |
| Kidney/renal pelvis | C64.9, 65.9 | 51 | 0.1 | 70 | 32 | 0.1 | 19 | 0.05 | 2.18 | (1.19–4.07)‡ |
| Bladder | C67.0–67.9 | 40 | 0.1 | 72 | <16 | ~ | 26 | 0.1 | ~ | |
| Eye/adnexa | C69.0–69.9 | 1,026 | 1.4 | 65 | 447 | 1.4 | 579 | 1.5 | 0.96 | (0.84–1.09) |
| Thyroid | C73.9 | 174 | 0.2 | 62 | 57 | 0.2 | 117 | 0.3 | 0.58 | (0.41–0.80)‡ |
Abbreviations: SEER-18, 18 cancer registry areas of the Surveillance, Epidemiology and End Results Program; ICD-O-3, International Classification of Diseases for Oncology, 3rd edition; n, number; IR, incidence rate; IRR, incidence rate ratio; CI, confidence interval; ~ IRs and IRRs not calculated for fewer than 16 cases; MZL, marginal zone lymphoma; HPV, human papillomavirus.
All incidence rates are age-adjusted to the 2000 US standard population and expressed per 1,000,000 person-years. Incidence rate ratios are based on unrounded rates. The table enumerates extranodal sites with ≥40 total cases. Extranodal sites (and ICD-O-3 topography) excluded from the table: lip (C00.0–00.9; n<16), hypopharynx (C12.9–13.9; n<16), other oral cavity/oropharynx (C14.0, 14.8; n<16), esophagus (C15.0–15.9; n<16), anus (C21.0–21.8; n<16), liver/intrahepatic bile ducts (C22.0–22.1; n=32; IR=0.05), gallbladder (C23.9; n<16), pancreas (C25.0–25.9; n<16), other digestive organs (C26.0–26.9; n=27; IR=0.4), nose/nasal cavity/middle ear (C30.0–30.1, 31.0–31.9; n=36; IR=0.05), larynx (C32.0–32.9; n<16), pleura (C38.4; n=20; IR=0.03); trachea/mediastinum/other respiratory (C33.9, 38.1–38.3, 38.8, 39.0, 39.8, 39.9; n<16), bones and joints (C40.0–41.9; n=24; IR=0.03), peritoneum/retroperitoneum (C48.0–48.8; n<16), vulva (C51.0–51.9; n<16), vagina (C52.9; n<16), cervix (C53.0–53.9; n<16), uterus (C54.0–54.9, 55.9; n<16), ovary (C56.9; n<16), prostate (C61.9; n=17; IR=0.02), testis (C62.0–62.9; n<16), other male genital (C63.0–63.9; n<16), ureter (C66.9; n<16), other urinary (C68.0–68.9; n<16), brain (C71.0–71.9; n=21; IR=0.03), cranial nerves/other nervous system (C70.0–70.9, 72.0–72.9; n=23; IR=0.03), other endocrine and thymus (C37.9, 74.0–75.9; n=20; IR=0.03), ill-defined sites (C76.0–76.9, n<16)
Cases of MZL coded to ICD-O-3 topography sites of blood (C42.0); bone marrow (C42.1); reticuloendothelial system, not otherwise specified (C42.3); haematopoietic system, not otherwise specified (C42.4); or unknown primary site (C80.9) (total n=194) are excluded from the “All nodal MZL” and “All extranodal MZL” categories.
95% CI excludes 1.00 (based on unrounded upper and lower CI), and IRR is significant (P<0.05).